Use of the piggy bac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral Vectors

Steven A. Feldman, Hui Xu, Mary A. Black, Tristen S. Park, Paul F. Robbins, James N. Kochenderfer, Richard A. Morgan, Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Efforts to improve the biosafety of γ-retroviral-mediated gene therapy have resulted in a shift toward the use of self-inactivating (SIN) γ-retroviral vectors. However, scale-up and manufacturing of such vectors requires significant optimization of transient transfection-based processes or development of novel platforms for the generation of stable producer cell clones. To that end, we describe the use of the piggybac transposon to generate stable producer cell clones for the production of SIN γ-retroviral vectors. The piggybac transposon is a universal tool allowing for the stable integration of SIN γ-retroviral constructs into murine (PG13) and human 293-based Phoenix (GALV and RD114, respectively) packaging cell lines without reverse transcription. Following transposition, a high-titer clone is selected for manufacture of a master cell bank and subsequent γ-retroviral vector supernatant production. Packaging cell clones created using the piggybac transposon have comparable titers to non-SIN vectors generated via conventional methods. We describe herein the use of the piggybac transposon for the production of stable packaging cell clones for the manufacture of clinical-grade SIN γ-retroviral vectors for ex vivo gene therapy clinical trials.

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalHuman Gene Therapy Methods
Volume25
Issue number4
DOIs
StatePublished - Aug 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Applied Microbiology and Biotechnology
  • Genetics
  • Pharmacology
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Use of the piggy bac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral Vectors'. Together they form a unique fingerprint.

Cite this